Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept

Mercedeh Bachai; Douglas R. Osmon; Donna M. Wolk; Lester E. Wold; George J. Haidukewych; Eric L. Matteson

doi:10.4065/76.6.653

Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept

Mercedeh Bachai, Douglas R. Osmon, Donna M. Wolk, Lester E. Wold, George J. Haidukewych, Eric L. Matteson

Research output: Contribution to journal › Article › peer-review

141 Scopus citations

Abstract

Patients with long-standing, severe, erosive rheumatoid arthritis who have extra-articular manifestations and have undergone joint replacement surgery are at increased risk for serious infection and premature mortality. New therapies, including cytokine antagonists, hold great promise for improving the course of rheumatoid arthritis. However, they have powerful anti-inflammatory effects that may mask symptoms of serious infection. We report a case of fatal pneumococcal sepsis occurring in a 37-year-old woman with rheumatoid arthritis treated with the tumor necrosis factor antagonist etanercept and suggest management strategies for early detection and management of this complication.

Original language	English (US)
Pages (from-to)	653-656
Number of pages	4
Journal	Mayo Clinic Proceedings
Volume	76
Issue number	6
DOIs	https://doi.org/10.4065/76.6.653
State	Published - 2001
Externally published	Yes

Keywords

DMARD = disease-modifying antirheumatic drug
NSAID = nonsteroidal anti-inflammatory drug
RA = rheumatoid arthritis
WBC = white blood cell

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.4065/76.6.653

Cite this

@article{22fa60c63bac419887c5492a037cbf69,

title = "Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept",

abstract = "Patients with long-standing, severe, erosive rheumatoid arthritis who have extra-articular manifestations and have undergone joint replacement surgery are at increased risk for serious infection and premature mortality. New therapies, including cytokine antagonists, hold great promise for improving the course of rheumatoid arthritis. However, they have powerful anti-inflammatory effects that may mask symptoms of serious infection. We report a case of fatal pneumococcal sepsis occurring in a 37-year-old woman with rheumatoid arthritis treated with the tumor necrosis factor antagonist etanercept and suggest management strategies for early detection and management of this complication.",

keywords = "DMARD = disease-modifying antirheumatic drug, NSAID = nonsteroidal anti-inflammatory drug, RA = rheumatoid arthritis, WBC = white blood cell",

author = "Mercedeh Bachai and Osmon, {Douglas R.} and Wolk, {Donna M.} and Wold, {Lester E.} and Haidukewych, {George J.} and Matteson, {Eric L.}",

year = "2001",

doi = "10.4065/76.6.653",

language = "English (US)",

volume = "76",

pages = "653--656",

journal = "Mayo Clinic Proceedings",

issn = "0025-6196",

publisher = "Elsevier Science",

number = "6",

}

TY - JOUR

T1 - Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept

AU - Bachai, Mercedeh

AU - Osmon, Douglas R.

AU - Wolk, Donna M.

AU - Wold, Lester E.

AU - Haidukewych, George J.

AU - Matteson, Eric L.

PY - 2001

Y1 - 2001

N2 - Patients with long-standing, severe, erosive rheumatoid arthritis who have extra-articular manifestations and have undergone joint replacement surgery are at increased risk for serious infection and premature mortality. New therapies, including cytokine antagonists, hold great promise for improving the course of rheumatoid arthritis. However, they have powerful anti-inflammatory effects that may mask symptoms of serious infection. We report a case of fatal pneumococcal sepsis occurring in a 37-year-old woman with rheumatoid arthritis treated with the tumor necrosis factor antagonist etanercept and suggest management strategies for early detection and management of this complication.

AB - Patients with long-standing, severe, erosive rheumatoid arthritis who have extra-articular manifestations and have undergone joint replacement surgery are at increased risk for serious infection and premature mortality. New therapies, including cytokine antagonists, hold great promise for improving the course of rheumatoid arthritis. However, they have powerful anti-inflammatory effects that may mask symptoms of serious infection. We report a case of fatal pneumococcal sepsis occurring in a 37-year-old woman with rheumatoid arthritis treated with the tumor necrosis factor antagonist etanercept and suggest management strategies for early detection and management of this complication.

KW - DMARD = disease-modifying antirheumatic drug

KW - NSAID = nonsteroidal anti-inflammatory drug

KW - RA = rheumatoid arthritis

KW - WBC = white blood cell

UR - http://www.scopus.com/inward/record.url?scp=0034995201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034995201&partnerID=8YFLogxK

U2 - 10.4065/76.6.653

DO - 10.4065/76.6.653

M3 - Article

C2 - 11393506

AN - SCOPUS:0034995201

VL - 76

SP - 653

EP - 656

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 6

ER -

Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this